The Recent Review of the Genitourinary Syndrome of Menopause
2
조회
0
다운로드
16
인용
0
참고문헌
키워드
초록
The genitourinary syndrome of menopause (GSM) is a new term that describes various menopausal symptoms and signs including not only genital symptoms (dryness, burning, and irritation), and sexual symptoms (lack of lubrication, discomfort or pain, and impaired function, but also urinary symptoms (urgency, dysuria, and recurrent urinary tract infections). The terms vulvovaginal atrophy and atrophic vaginitis, which were generally used until recently, had a limitation because they did not cover the full spectrum of symptoms and did not imply that the symptoms are related to a decreased estrogen level in menopause. Since the GSM may have a profound negative impact on the quality of life of postmenopausal women, women should be made aware of these problems and treated with an appropriate effective therapy. Thus, in this review we introduce new terminology and discuss the importance of comprehension of GSM and the necessity of active treatment of this syndrome in postmenopausal women. (J Menopausal Med 2015;21:65-71)
Abstract
The genitourinary syndrome of menopause (GSM) is a new term that describes various menopausal symptoms and signs including not only genital symptoms (dryness, burning, and irritation), and sexual symptoms (lack of lubrication, discomfort or pain, and impaired function, but also urinary symptoms (urgency, dysuria, and recurrent urinary tract infections). The terms vulvovaginal atrophy and atrophic vaginitis, which were generally used until recently, had a limitation because they did not cover the full spectrum of symptoms and did not imply that the symptoms are related to a decreased estrogen level in menopause. Since the GSM may have a profound negative impact on the quality of life of postmenopausal women, women should be made aware of these problems and treated with an appropriate effective therapy. Thus, in this review we introduce new terminology and discuss the importance of comprehension of GSM and the necessity of active treatment of this syndrome in postmenopausal women. (J Menopausal Med 2015;21:65-71)
참고문헌 (37)
- Portman DJ., "Genitourinary syndrome of menopause : new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society", Menopause, 21, pp.1063~1068 (2014)
- Nappi RE., "Women's voices in the menopause : results from an international survey on vaginal atrophy", Maturitas, 67, pp.233~238 (2010)
- Nappi RE., "Vaginal Health : Insights, Views & Attitudes(VIVA)-results from an international survey", Climacteric, 15, pp.36~44 (2012)
- Kingsberg SA., "Vulvar and vaginal atrophy in postmenopausal women : findings from the REVIVE(REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs)survey", J Sex Med, 10, pp.1790~1799 (2013)
- 채희동, "Awareness and Experience of Menopausal Symptom and Hormone Therapy in Korean Postmenopausal Women", 대한폐경학회지, 20(1), pp.7~13 (2014), 대한폐경학회
- Nappi RE., "Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause", Climacteric, 17, pp.3~9 (2014)
- Tan O., "Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women : an up-to-date review", Menopause, 19, pp.109~117 (2012)
- Levine KB., "Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women", Menopause, 15, pp.661~666 (2008)
- Avis NE., "Longitudinal changes in sexual functioning as women transition through menopause : results from the Study of Women's Health Across the Nation", Menopause, 16, pp.442~452 (2009)
- Robinson D., "The role of estrogens in female lower urinary tract dysfunction", Urology, 62, pp.45~51 (2003)
- Hyun HS., "Urodynamic characterization of postmenopausal women with stress urinary incontinence : retrospective study in incontinent pre-and post-menopausal women", J Korean Soc Menopause, 16, pp.148~152 (2010)
- Brown JS., "Urinary tract infections in postmenopausal women : effect of hormone therapy and risk factors", Obstet Gynecol, 98, pp.1045~1052 (2001)
- Raul Raz, "Urinary Tract Infection in Postmenopausal Women", Investigative and Clinical Urology, 52(12), pp.801~808 (2011), 대한비뇨기과학회
- Lüthje P., "Estrogenic action on innate defense mechanisms in the urinary tract", Maturitas, 77, pp.32~36 (2014)
- 김미영, "The Demographic Changes of Menopausal and Geripausal Women in Korea", 대한골대사학회지, 22(1), pp.23~28 (2015), 대한골대사학회[DOI]
- Sturdee DW., "Recommendations for the management of postmenopausal vaginal atrophy", Climacteric, 13, pp.509~522 (2010)
- Nappi RE., "The CLOSER(CLarifying Vaginal Atrophy's Impact On SEx and Relationships)survey : implications of vaginal discomfort in postmenopausal women and in male partners", J Sex Med, 10, pp.2232~2241 (2013)
- The North American Menopause Society., "Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society", Menopause, 20, pp.888~902 (2013)
- Cody JD., "Oestrogen therapy for urinary incontinence in postmenopausal women", Cochrane Database Syst Rev, 10, pp.Cd001405~ (2012)
- Beerepoot MA., "Nonantibiotic prophylaxis for recurrent urinary tract infections : a systematic review and metaanalysis of randomized controlled trials", J Urol, 190, pp.1981~1989 (2013)
- 홍성남, "폐경기 여성에서 승마 물질의 비뇨기 위축과 부작용에 대한 효과", 대한폐경학회지, 18(2), pp.106~112 (2012), 대한폐경학회[DOI]
- The North American Menopause Society., "The 2012 hormone therapy position statement of : The North American Menopause Society", Menopause, 19, pp.257~271 (2012)
- Brown JS., "Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen", Progestin Replacement Study(HERS)Research Group, 1999, pp.94, 66~70
- Hendrix SL., "Effects of estrogen with and without progestin on urinary incontinence", JAMA, 293, pp.935~948 (2005)
- Pinkerton JV., "Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy", Menopause, 21, pp.309~319 (2014)
- Mirkin S., "Tissue-selective estrogen complexes for postmenopausal women", Maturitas, 76, pp.213~220 (2013)
- Constantine G., "Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy : results of a randomized, placebocontrolled trial", Climacteric, 18, pp.226~232 (2015)
- Portman DJ., "Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy", Menopause, 20, pp.623~630 (2013)
- Simon JA., "One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus", Menopause, 20, pp.418~427 (2013)
- Archer DF., "Tissue-selective estrogen complexes : a promising option for the comprehensive management of menopausal symptoms", Drugs Aging, 27, pp.533~544 (2010)
- Lobo RA., "Evaluation of bazedoxifene", conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile, 2009, pp.92, 1025~1038
- Rahn DD., "Vaginal estrogen for genitourinary syndrome of menopause : a systematic review", Obstet Gynecol, 124, pp.1147~1156 (2014)
- Grimaldi EF., "Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort", Minerva Ginecol, 64, pp.321~329 (2012)
- Chen J., "Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness : a multicenter, randomized, controlled, open-label, parallel-group, clinical trial", J Sex Med, 10, pp.1575~1584 (2013)
- Johnston SL., "The detection and management of vaginal atrophy", J Obstet Gynaecol Can, 26, pp.503~515 (2004)
- Suckling J., "Local oestrogen for vaginal atrophy in postmenopausal women", Cochrane Database Syst Rev, 2006, pp.Cd001500~ (2006)
- Sinha A., "Non-hormonal topical treatment of vulvovaginal atrophy : an up-to-date overview", Climacteric, 16, pp.305~312 (2013)